Literature DB >> 8557364

Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR.

D W Acheson1, M M Levine, J B Kaper, G T Keusch.   

Abstract

This study addresses a mechanism for inducing systemic immunity to Shiga-like toxins by oral administration of a Shiga-like toxin I B-subunit-expressing Vibrio cholerae vaccine strain [CVD 103-HgR(pDA60)]. Two sets of three rabbits were given either CVD 103-HgR or CVD 103-HgR(pDA60) orally. All rabbits immunized with CVD 103-HgR(pDA60) developed neutralizing serum antibodies to Shiga-like toxin I. None of the controls developed such antibodies.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8557364      PMCID： PMC173768          DOI： 10.1128/iai.64.1.355-357.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  19 in total

1.  Pathogenesis of Shigella diarrhea. XVI. Selective targetting of Shiga toxin to villus cells of rabbit jejunum explains the effect of the toxin on intestinal electrolyte transport.

Authors:  G Kandel; A Donohue-Rolfe; M Donowitz; G T Keusch
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

2.  Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.

Authors:  M M Levine; J B Kaper; D Herrington; J Ketley; G Losonsky; C O Tacket; B Tall; S Cryz
Journal:  Lancet       Date:  1988-08-27       Impact factor: 79.321

3.  Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins.

Authors:  Y Endo; K Tsurugi; T Yutsudo; Y Takeda; T Ogasawara; K Igarashi
Journal:  Eur J Biochem       Date:  1988-01-15

4.  Globotriosyl ceramide is specifically recognized by the Escherichia coli verocytotoxin 2.

Authors:  T Waddell; S Head; M Petric; A Cohen; C Lingwood
Journal:  Biochem Biophys Res Commun       Date:  1988-04-29       Impact factor: 3.575

5.  Direct cytotoxic action of Shiga toxin on human vascular endothelial cells.

Authors:  T G Obrig; P J Del Vecchio; J E Brown; T P Moran; B M Rowland; T K Judge; S W Rothman
Journal:  Infect Immun       Date:  1988-09       Impact factor: 3.441

6.  Expression and purification of Shiga-like toxin II B subunits.

Authors:  D W Acheson; S A De Breucker; M Jacewicz; L L Lincicome; A Donohue-Rolfe; A V Kane; G T Keusch
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

7.  Colonic biopsy in verotoxin-induced hemorrhagic colitis and thrombotic thrombocytopenic purpura (TTP).

Authors:  D M Morrison; D L Tyrrell; L D Jewell
Journal:  Am J Clin Pathol       Date:  1986-07       Impact factor: 2.493

8.  Quantitative microtiter cytotoxicity assay for Shigella toxin.

Authors:  M K Gentry; J M Dalrymple
Journal:  J Clin Microbiol       Date:  1980-09       Impact factor: 5.948

Review 9.  Infection by verocytotoxin-producing Escherichia coli.

Authors:  M A Karmali
Journal:  Clin Microbiol Rev       Date:  1989-01       Impact factor: 26.132

10.  Pathogenesis of shigella diarrhea. XI. Isolation of a shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide.

Authors:  M Jacewicz; H Clausen; E Nudelman; A Donohue-Rolfe; G T Keusch
Journal:  J Exp Med       Date:  1986-06-01       Impact factor: 14.307
View more
  22 in total

1.  Haemolytic uraemic syndrome and E coli O157.

Authors:  M Fitzpatrick
Journal:  BMJ       Date:  1999-03-13

2.  Development of recombinant B subunit of Shiga-like toxin 1 as a probe to detect carbohydrate ligands in immunochemical and flowcytometric application.

Authors:  S Miyashita; Y Matsuura; D Miyamoto; Y Suzuki; Y Imai
Journal:  Glycoconj J       Date:  1999-11       Impact factor: 2.916

3.  Protection against Shiga toxin 1 challenge by immunization of mice with purified mutant Shiga toxin 1.

Authors:  Satoshi Ishikawa; Kazuyoshi Kawahara; Yutaka Kagami; Yasunori Isshiki; Aki Kaneko; Hidenori Matsui; Nobuhiko Okada; Hirofumi Danbara
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

4.  Protection against Escherichia coli O157:H7 challenge by immunization of mice with purified Tir proteins.

Authors:  Hong-Ying Fan; Ling Wang; Jun Luo; Bei-Guo Long
Journal:  Mol Biol Rep       Date:  2011-05-13       Impact factor: 2.316

5.  Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain.

Authors:  E T Ryan; J R Butterton; R N Smith; P A Carroll; T I Crean; S B Calderwood
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

6.  Localization of intravenously administered verocytotoxins (Shiga-like toxins) 1 and 2 in rabbits immunized with homologous and heterologous toxoids and toxin subunits.

Authors:  M Bielaszewska; I Clarke; M A Karmali; M Petric
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

7.  Murine antibody responses to the verotoxin 1 B subunit: demonstration of major histocompatibility complex dependence and an immunodominant epitope involving phenylalanine 30.

Authors:  D J Bast; J Sandhu; N Hozumi; B Barber; J Brunton
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

8.  Protection by a recombinant Mycobacterium bovis Bacillus Calmette-Guerin vaccine expressing Shiga toxin 2 B subunit against Shiga toxin-producing Escherichia coli in mice.

Authors:  Jun Fujii; Mariko Naito; Takashi Yutsudo; Sohkichi Matsumoto; Daniel P Heatherly; Takeshi Yamada; Hideyuki Kobayashi; Shin-Ichi Yoshida; Tom Obrig
Journal:  Clin Vaccine Immunol       Date:  2012-10-03

9.  A DNA vaccine encoding the enterohemorragic Escherichia coli Shiga-like toxin 2 A2 and B subunits confers protective immunity to Shiga toxin challenge in the murine model.

Authors:  Leticia V Bentancor; Marcos Bilen; Romina J Fernández Brando; María Victoria Ramos; Luis C S Ferreira; Pablo D Ghiringhelli; Marina S Palermo
Journal:  Clin Vaccine Immunol       Date:  2009-01-28

10.  Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108.

Authors:  Weili Liang; Shixia Wang; Fenggang Yu; Lijuan Zhang; Guoming Qi; Yanqing Liu; Shouyi Gao; Biao Kan
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.